Research ExplorerPublicationsAllogeneic hematopoietic stem-cell transplantation in patien...

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

Standard

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. / Casper, Jochen; Wolff, Daniel; Knauf, Wolfgang; Blau, Igor W; Ruutu, Tapani; Volin, Liisa; Wandt, Hannes; Schäfer-Eckart, Kerstin; Holowiecki, Jerzy; Giebel, Sebastian; Aschan, Johan; Zander, Axel R.; Kröger, Nicolaus; Hilgendorf, Inken; Baumgart, Joachim; Mylius, Heidrun A; Pichlmeier, Uwe; Freund, Mathias.

In: J CLIN ONCOL, Vol. 28, No. 20, 20, 2010, p. 3344-3351.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Casper, J, Wolff, D, Knauf, W, Blau, IW, Ruutu, T, Volin, L, Wandt, H, Schäfer-Eckart, K, Holowiecki, J, Giebel, S, Aschan, J, Zander, AR, Kröger, N, Hilgendorf, I, Baumgart, J, Mylius, HA, Pichlmeier, U & Freund, M 2010, 'Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.', J CLIN ONCOL, vol. 28, no. 20, 20, pp. 3344-3351. <http://www.ncbi.nlm.nih.gov/pubmed/20498405?dopt=Citation>

APA

Casper, J., Wolff, D., Knauf, W., Blau, I. W., Ruutu, T., Volin, L., Wandt, H., Schäfer-Eckart, K., Holowiecki, J., Giebel, S., Aschan, J., Zander, A. R., Kröger, N., Hilgendorf, I., Baumgart, J., Mylius, H. A., Pichlmeier, U., & Freund, M. (2010). Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J CLIN ONCOL, 28(20), 3344-3351. [20]. http://www.ncbi.nlm.nih.gov/pubmed/20498405?dopt=Citation

Vancouver

Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J CLIN ONCOL. 2010;28(20):3344-3351. 20.

Bibtex

@article{c626c107b8ba405eb1a1e947e6a86af0,
title = "Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.",
abstract = "Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 x 10 g/m(2) was the basis for dose escalation in this prospective, multicenter trial.",
author = "Jochen Casper and Daniel Wolff and Wolfgang Knauf and Blau, {Igor W} and Tapani Ruutu and Liisa Volin and Hannes Wandt and Kerstin Sch{\"a}fer-Eckart and Jerzy Holowiecki and Sebastian Giebel and Johan Aschan and Zander, {Axel R.} and Nicolaus Kr{\"o}ger and Inken Hilgendorf and Joachim Baumgart and Mylius, {Heidrun A} and Uwe Pichlmeier and Mathias Freund",
year = "2010",
language = "Deutsch",
volume = "28",
pages = "3344--3351",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

RIS

TY - JOUR

T1 - Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

AU - Casper, Jochen

AU - Wolff, Daniel

AU - Knauf, Wolfgang

AU - Blau, Igor W

AU - Ruutu, Tapani

AU - Volin, Liisa

AU - Wandt, Hannes

AU - Schäfer-Eckart, Kerstin

AU - Holowiecki, Jerzy

AU - Giebel, Sebastian

AU - Aschan, Johan

AU - Zander, Axel R.

AU - Kröger, Nicolaus

AU - Hilgendorf, Inken

AU - Baumgart, Joachim

AU - Mylius, Heidrun A

AU - Pichlmeier, Uwe

AU - Freund, Mathias

PY - 2010

Y1 - 2010

N2 - Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 x 10 g/m(2) was the basis for dose escalation in this prospective, multicenter trial.

AB - Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 x 10 g/m(2) was the basis for dose escalation in this prospective, multicenter trial.

M3 - SCORING: Zeitschriftenaufsatz

VL - 28

SP - 3344

EP - 3351

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 20

M1 - 20

ER -